HEARTBiT: A Transcriptomic Signature for Excluding Acute Cellular Rejection in Adult Heart Allograft Patients

ConclusionsHEARTBiT’s diagnostic performance compares favourably to the only currently approved, minimally-invasive diagnostic test to rule out ACR, AlloMap, and may be used to inform care decisions in the first 2 months post-transplantation, when AlloMap is not approved, and most ACR episodes occur.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research